{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=9", "query": { "condition": "Phase IB", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 1612, "total_pages": 162, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T04:24:42.044Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02124850", "title": "A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Motolimod", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-10-28", "completion_date": "2016-10-31", "has_results": false, "last_update_posted_date": "2019-10-25", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124850" }, { "nct_id": "NCT03908333", "title": "High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer", "Pancreatic Cancer", "Pancreas Cancer", "Pancreatic Adenocarcinoma Resectable", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Metastasis" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Paclitaxel protein-bound", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-05-01", "completion_date": "2023-05-01", "has_results": false, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • San Diego, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fayetteville", "state": "Georgia" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03908333" }, { "nct_id": "NCT03024216", "title": "Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Atezolizumab1200 mg IV", "type": "DRUG" }, { "name": "Sipuleucel-T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 37, "start_date": "2017-02-06", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2021-05-26", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 3, "location_summary": "Duarte, California • Marina del Rey, California • Honolulu, Hawaii", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Marina del Rey", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT03024216" }, { "nct_id": "NCT01791478", "title": "BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Invasive Ductal Breast Carcinoma", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "PI3K inhibitor BYL719", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 46, "start_date": "2013-04", "completion_date": "2022-10-06", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01791478" }, { "nct_id": "NCT03345784", "title": "Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Carcinoma", "Endometrioid Adenocarcinoma", "Malignant Female Reproductive System Neoplasm", "Recurrent Cervical Carcinoma", "Stage I Uterine Corpus Cancer AJCC v7", "Stage I Vaginal Cancer AJCC v6 and v7", "Stage IA Uterine Corpus Cancer AJCC v7", "Stage IB Cervical Cancer AJCC v6 and v7", "Stage IB Uterine Corpus Cancer AJCC v7", "Stage IB2 Cervical Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage II Vaginal Cancer AJCC v6 and v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage III Cervical Cancer AJCC v6 and v7", "Stage III Uterine Corpus Cancer AJCC v7", "Stage III Vaginal Cancer AJCC v6 and v7", "Stage IIIA Cervical Cancer AJCC v6 and v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Vaginal Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2018-05-29", "completion_date": "2022-05-10", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 6, "location_summary": "Sacramento, California • Aurora, Colorado • Lexington, Kentucky + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345784" }, { "nct_id": "NCT05916313", "title": "A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "BI 764532", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-01-30", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 2, "location_summary": "Orange, California • Nashville, Tennessee", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05916313" }, { "nct_id": "NCT07259304", "title": "Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Central Nervous System Neoplasm", "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Hodgkin Lymphoma", "Malignant Bone Neoplasm", "Malignant Brain Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Non-Hodgkin Lymphoma", "Pathologic Stage I Cutaneous Melanoma AJCC v8", "Pathologic Stage IA Cutaneous Melanoma AJCC v8", "Pathologic Stage IB Cutaneous Melanoma AJCC v8", "Pathologic Stage II Cutaneous Melanoma AJCC v8", "Pathologic Stage IIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIC Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Cervical Cancer AJCC v8", "Stage I Colorectal Cancer AJCC v8", "Stage I Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage I Ovarian Cancer AJCC v8", "Stage I Thyroid Gland Medullary Carcinoma AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Ovarian Cancer AJCC v8", "Stage IB Uterine Corpus Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage II Thyroid Gland Medullary Carcinoma AJCC v8", "Stage II Uterine Corpus Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Colorectal Cancer AJCC v8", "Stage IIA Ovarian Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Colorectal Cancer AJCC v8", "Stage IIB Ovarian Cancer AJCC v8", "Stage IIC Colorectal Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 173, "start_date": "2021-11-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 3, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07259304" }, { "nct_id": "NCT02432950", "title": "Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Dietary Intervention", "type": "DIETARY_SUPPLEMENT" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 21, "start_date": "2016-03-22", "completion_date": "2022-12-19", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02432950" }, { "nct_id": "NCT02078089", "title": "Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Morphine", "type": "DRUG" }, { "name": "Oxcarbazepine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Costantine Albany", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-03-06", "completion_date": "2014-12-11", "has_results": false, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 2, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02078089" }, { "nct_id": "NCT03502733", "title": "Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-08-14", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-06T04:24:42.044Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03502733" } ] }